Consumer Health Information www.fda.gov/consumer about the potential for using nicotine replacement therapies.
OTC nicotine replacement products are sold under brand names and private labels, and as generic products. They are approved for sale to persons 18 years of age and older.
OTC nicotine replacement products include
• skin patches available as generics known as transdermal nicotine patches, as private-label products, and under the brand names Habitrol and Nicoderm. These patches are affixed to the skin, similar to how you would apply an adhesive bandage
• chewing gum available as a generic product known as nicotine gum, as private-label products, and under the brand name Nicorette
• lozenges available as generics known as nicotine lozenges, as private-label products, and under the brand name Commit
Prescription-only nicotine replacement products are available only under the brand name Nicotrol and are available both as a nasal spray and an oral inhaler.
There is important advice to consider before beginning a nicotine replacement therapy.
• You should stop using a nicotine replacement product and call your health care professional if you experience nausea, dizziness, weakness, vomiting, fast or irregular heartbeat, mouth problems with the lozenge or gum, or redness or swelling of the skin around the patch that does not go away.
• Don’t use any other product containing nicotine while using a nicotine replacement product.
• Women who are pregnant or breastfeeding should use these products only with approval from their health care professional.
• Talk to your health care professional before using these products if you have
· diabetes, heart disease, asthma, or stomach ulcers
· had a recent heart attack
· high blood pressure that is not controlled with medicine
· a history of irregular heartbeat
• If you take prescription medication for depression or asthma, let your health care professional know if you are quitting smoking; your prescription dose may need to be adjusted.
Products Not Containing Nicotine
Two medicines that do not contain nicotine have FDA’s approval as smoking cessation products. They are Chantix (varenicline tartrate) and Zyban (buproprion). Both are available in tablet form on a prescription-only basis.
In July 2009, FDA required both products to carry new safety information in a boxed warning on their labeling for health care professionals citing serious risks for users taking these drugs. These risks include changes in behavior, depressed mood, hostility, and suicidal thoughts or actions.
Read the product’s patient medication guide in its entirety if you use or plan to use either Chantix or Zyban. These guides offer important information on adverse affects, risks, warnings, product ingredients, and what you should talk about with your health care professional before taking the products.
Chantix acts at sites in the brain affected by nicotine. It provides some nicotine effects to ease withdrawal symptoms and blocks the effects of nicotine from cigarettes if users resume smoking.
The medication guide for Chantix states that the product is not recommended for people under 18 years of age.
The most common side effects of Chantix include nausea; constipation; gas; vomiting; and trouble sleeping or vivid, unusual, or strange dreams.
In addition to the warnings about changes in behavior, depressed mood, hostility, and suicidal thoughts or actions when taking this drug, the patient medication guide for Chantix cites other adverse affects and risks— including allergic reactions, serious skin reactions, and trouble driving or operating heavy machinery.
Stop taking Chantix and call your health care professional right away if you notice any of these symptoms, or develop other symptoms included in the medication guide for patients.
Zyban helps patients to abstain from smoking; however, the precise means by which it accomplishes this is unknown.
The medication guide for Zyban states that the product has not been studied in children under the age of 18 and is not approved for use in children and teenagers.
The most commonly observed adverse events consistently associated with the use of Zyban are dry mouth and insomnia.
In addition to warnings about the risks of serious psychiatric problems, the medication guide for Zyban cites other adverse events and risks related to this product, including seizures, high blood pressure, and allergic reactions.
Since Zyban contains the same active ingredient as the antidepressant Wellbutrin, users and potential users are urged to talk to their health care professional about risks and benefits of treatment with antidepressant medicines.
This article appears on FDA’s Consumer Updates page (www.fda. gov/ForConsumers/ConsumerUpdates), which features the latest on all FDA-regulated products.
For More Information
www.smokefree.gov, www.women.smokefree.gov
Helping You Quit
www.fda.gov/TobaccoProducts/ ucm173429.htm
FDA Warns of Health Risks Posed by E-Cigarettes
www.fda.gov/ForConsumers/ ConsumerUpdates/ucm173401.htm